This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Onvansertib
DrugBank Accession Number
DB15110
Background

Onvansertib is under investigation in clinical trial NCT03303339 (Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 532.5182
Monoisotopic: 532.215821385
Chemical Formula
C24H27F3N8O3
Synonyms
  • Onvansertib

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
67RM91WDHQ
CAS number
1034616-18-6
InChI Key
QHLVBNKYJGBCQJ-UHFFFAOYSA-N
InChI
InChI=1S/C24H27F3N8O3/c1-33-6-8-34(9-7-33)15-3-5-18(38-24(25,26)27)17(12-15)30-23-29-13-14-2-4-16-20(22(28)37)32-35(10-11-36)21(16)19(14)31-23/h3,5,12-13,36H,2,4,6-11H2,1H3,(H2,28,37)(H,29,30,31)
IUPAC Name
1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)phenyl]amino}-1H,4H,5H-pyrazolo[4,3-h]quinazoline-3-carboxamide
SMILES
CN1CCN(CC1)C1=CC(NC2=NC=C3CCC4=C(N(CCO)N=C4C(N)=O)C3=N2)=C(OC(F)(F)F)C=C1

References

General References
Not Available
ChemSpider
26325993
BindingDB
50343559
ChEMBL
CHEMBL1738758
ZINC
ZINC000043196885
PDBe Ligand
937
PDB Entries
2yac

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer (CRPC)1
2RecruitingTreatmentPancreatic Adenocarcinoma (Ductal Adenocarcinoma)1
1, 2CompletedTreatmentAcute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentKRAS Gene Mutation / Metastatic Colorectal Cancer (CRC)1
0RecruitingTreatmentBorderline Resectable Pancreatic Adenocarcinoma / Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) / Metastatic Pancreatic (Ductal) Adenocarcinoma / Resectable Pancreatic Ductal Adenocarcinoma (PDAC) / Stage I Pancreatic Cancer AJCC v8 / Stage IA Pancreatic Cancer AJCC v8 / Stage IB Pancreatic Cancer AJCC v8 / Stage II Pancreatic Cancer AJCC v8 / Stage IIA Pancreatic Cancer AJCC v8 / Stage IIB Pancreatic Cancer AJCC v8 / Stage III Pancreatic Cancer AJCC v8 / Stage IV Pancreatic Cancer AJCC v81
Not AvailableNo Longer AvailableNot AvailableKRAS Gene Mutation / Metastatic Colorectal Cancer (CRC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0522 mg/mLALOGPS
logP2.21ALOGPS
logP3.05ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)12.65ChemAxon
pKa (Strongest Basic)7.81ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area134.66 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity141.53 m3·mol-1ChemAxon
Polarizability53.02 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at May 20, 2019 14:50 / Updated at February 21, 2021 18:55